Pavinetant - Millendo Therapeutics

Drug Profile

Pavinetant - Millendo Therapeutics

Alternative Names: AZ 12472520; AZD 2624; AZD 4901; MLE4901

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Millendo Therapeutics
  • Class Small molecules
  • Mechanism of Action Hormone modulators; Neurokinin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hot flashes; Polycystic ovary syndrome; Schizophrenia

Most Recent Events

  • 08 Nov 2017 Discontinued - Phase-II for Hot flashes in United Kingdom (PO)
  • 08 Nov 2017 Discontinued - Phase-II for Polycystic ovary syndrome in USA, Germany, United Kingdom (PO)
  • 08 Nov 2017 Millendo Therapeutics terminates a phase II trial in Hot flashes in United Kingdom after assessment of the clinical risks and benefits of the program (PO) (NCT02668185)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top